Technology

Cytokinetics

$18.81
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.84 (-4.24%) Today
-$0.15 (-0.79%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Cytokinetics and other stocks, options, and ETFs commission-free!

About CYTK

Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA. The listed name for CYTK is Cytokinetics, Incorporated Common Stock.

CEO
Robert I. Blum
Employees
156
Headquarters
South San Francisco, California
Founded
1997
Market Cap
1.31B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
937.83K
High Today
$20.46
Low Today
$18.89
Open Price
$19.74
Volume
743.24K
52 Week High
$30.14
52 Week Low
$8.00

Collections

CYTK Earnings

-$0.68
-$0.45
-$0.23
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 4, After Hours

You May Also Like

PBUS
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure